{"id":391551,"date":"2014-09-18T00:00:00","date_gmt":"2014-09-18T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/straxx1214-biopharma-biomarkers-for-emerging-biologics-for-severe-refractory-asthma\/"},"modified":"2026-03-31T09:04:41","modified_gmt":"2026-03-31T09:04:41","slug":"straxx1214-biopharma-biomarkers-for-emerging-biologics-for-severe-refractory-asthma","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/straxx1214-biopharma-biomarkers-for-emerging-biologics-for-severe-refractory-asthma\/","title":{"rendered":"Biomarkers for Emerging Biologics for Severe\/Refractory Asthma"},"content":{"rendered":"<p>The use of biomarkers and personalized medicine is at a very early stage in asthma. Although most asthma patients can obtain disease control through treatment with available therapies, there remains a high unmet need for more-individualized therapies and therapeutic regimens that can be used in severe subpopulations of the heterogeneous asthma population. <\/p>\n<p>Although severe\/refractory patients represent only a subset of the asthma population, novel agents that target this patient segment have the potential to command price premiums given these patients\u2019 level of unmet need. As a result, a series of biologics targeted at specific subpopulations of asthma patients (e.g., IL-5 inhibitors for eosinophilic asthma patients, IL-13 inhibitors for severe asthma patients with elevated periostin or dipeptidyl peptidase-4 [DPP-4]). These targeted agents are being developed with the intention of using them in patients who express a particular biomarker. The development of targeted biologics represents the most active space in asthma research.<\/p>\n","protected":false},"template":"","class_list":["post-391551","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-asthma","biopharma-date-574"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/391551","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/391551\/revisions"}],"predecessor-version":[{"id":394674,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/391551\/revisions\/394674"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=391551"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}